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The limited efficacy of available antidepressant therapies may be due to how they affect the underlying 
brain network. the purpose of this study was to develop a melancholic MDD biomarker to identify 
critically important functional connections (fcs), and explore their association to treatments. Resting 
state fMRI data of 130 individuals (65 melancholic major depressive disorder (MDD) patients, 65 
healthy controls) were included to build a melancholic MDD classifier, and 10 FCs were selected by 
our sparse machine learning algorithm. this biomarker generalized to a drug-free independent cohort 
of melancholic MDD, and did not generalize to other MDD subtypes or other psychiatric disorders. 
Moreover, we found that antidepressants had a heterogeneous effect on the identified FCs of 25 
melancholic MDDs. in particular, it did impact the fc between left dorsolateral prefrontal cortex 
(DLpfc)/inferior frontal gyrus (ifG) and posterior cingulate cortex (pcc)/precuneus, ranked as the 
second ‘most important’ fc based on the biomarker weights, whilst other eight fcs were normalized. 
Given that left DLpfc has been proposed as an explicit target of depression treatments, this suggest 
that the limited efficacy of antidepressants might be compensated by combining therapies with 
targeted treatment as an optimized approach in the future.
Major depressive disorder remains a major global health challenge, with substantial socio-economic 
cost. The mainstay of pharmacological treatment is selective serotonin reuptake inhibitors (SSRIs) and 
serotonin-norepinephrine reuptake inhibitor (SNRIs). Despite their widespread and increasing use1–4, many 
patients respond little, if at all5,6. Understanding why this is the case is complicated, because of the poorly under-
stood relationship between the regionally distributed actions of drugs and the complex underlying neurobiology 
of depressive symptoms.
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Recently, brain imaging has provided important insights into the underlying neural mechanisms of depres-
sion. In particular, resting-state connectivity studies in humans have identified a number of potentially impor-
tant abnormal functional connections that may play a role in disorder symptoms7–14. However, according to the 
meta-analysis paper of MRI-based neuroimaging biomarkers in depressive disorders15, around 30% of reviewed 
papers were using resting-state fMRI (rsfMRI) as modality, and only one-third of them were using functional 
connections (FCs) among region of interests (ROIs) as features. As most of those biomarker studies applied the 
algorithm of support vector machine (SVM) to achieve high accuracy with many features, it has not yet been clear 
about which are the most critical FCs in depression with whole-brain analysis.
In order to determine target FCs and investigate their modulation by antidepressants, it would be important 
to focus on a specific subtype of depression, because of heterogeneity of depression. Melancholic major depressive 
disorder (MDD) is a subtype of MDD that is traditionally considered to be the most drug-responsive, and so pro-
vides an ideal target to probe the effect of drugs on abnormal connectivity16–20. Reliably identifying drug effects 
on connectivity requires a robust biomarker that directly maps connectivity patterns to depressive symptoms.
As hypotheses on modulation by antidepressants, one possibility is that abnormal connectivity in MDD is uni-
formly but only partially resolved following treatment. On the other hand, it may be that whilst some functional 
connections fully resolve, others do not, or are even worsened by treatment. This latter possibility is particularly 
intriguing since it would suggest that the relative effect on different functional connections determines treatment 
response, as well as identifying specific targets for future combined treatment approaches. Therefore, the purpose 
of this study is to develop a melancholic MDD biomarker based on functional connections and explore the sen-
sitivity to treatment.
In theory, this could identify functional connections which would be potential targets of depression treatment. 
This is because, first, the resting state functional connectivity is temporal correlations between two brain regions 
of interests (ROIs), and it is flexibly changed based on the type of cognitive tasks and easily can be targeted in 
training or intervention treatment studies in a short period of time. Second, there have been more and more 
interests in studying the network brain activity in fMRI data. The main functional networks are default mode 
network (DMN), executive control network (ECN), and salience network (SN). Specifically, DMN is observed as 
the network of regions functionally connected with each other during rest (i.e., with correlations of spontaneous 
temporal fluctuations of BOLD signals), and it is known to be correlated with depression symptom severity in 
recurrent MDDs21. So, some critical FCs in DMN could be both a good diagnostic measure and a good treat-
ment target. Third, it has been reported that the change of within-DMN functional connectivity extends to other 
regions in the default mode modules, and also associated with FCs in the fronto-parietal module22. This suggests 
the possibility that we may be able to target and focus on only a critically abnormal FC to normalize, in order to 
affect the whole DMN to reduce depressive symptoms. At the same time, however, it is important to point out 
that functional connectivity studies are purely correlative even for the predictive diagnosis classification, and it 
should be difficult to disentangle causal versus consequential changes which track behavior and symptoms. To the 
best of our knowledge, there is no answer yet to the question if abnormality of functional connection is a cause of 
depression or an epiphenomenon caused by depression. However, based on the following reasons, we think that it 
would be appropriate to target the functional connection which is diagnostically most reliable. Although there is a 
limitation that we cannot really know if the correlational relationship could be causal, more and more researchers 
are focusing on the brain networks and abnormality of neural circuit dynamics, as a key for successful analysis to 
integrate different levels of knowledge into a comprehensive system23–25. Before such prospects, much more work 
is needed in fact, and we hope our work can contribute to the movement.
Our aims in this study were therefore two-fold: first, to extract critically important functional connections 
when building a classifier of melancholic MDD; and second, to use it to test the uniformity versus heterogeneity 
connectivity hypotheses of the effect of antidepressants on melancholic MDD patients.
Methods
participants and clinical measures. The overview of depression biomarker development is shown in 
Fig. 1. 177 patients were recruited at the Hiroshima University Hospital and local clinics (in Hiroshima, Japan) 
and screened using the M.I.N.I.26,27 for a MDD diagnosis with the DSM-IV criteria. Out of them, 118 patients 
participated in the MRI experiments. Exclusion criteria included current or past manic episodes; psychotic epi-
sodes; alcohol dependence or/and abuse; substance dependence or/and abuse; and antisocial personality disorder 
based on M.I.N.I., change of diagnosis (from unipolar to bipolar depression), MRI scan after more than 2 weeks 
of medication, fMRI data with excessive head motions based on scrubbing results (see the following section of 
Neuroimaging data preprocessing and interregional correlations). In addition, as the exclusion criteria at the 
moment of recruitment at local clinics included: already enough amount of dose and time of one type of anti-
depressant was administered, more than 2 types of antidepressants were administered for the current episode, 
had electroconvulsive therapy (ECT), physical disorders which may have any negative effects with SSRI treat-
ments, current pregnancy or breast-feeding, high risk of suicidality judged by the doctor, those who needed to 
be hospitalized, and those who were not able to understand Japanese expressions. 92 patients with more than 
mild depressive symptoms (i.e., BDI >= 17) were included in the dataset of training the MDD classifier in the 
end. Patients had an initial MRI scan before or after starting medication within 0–2 weeks. 171 healthy controls 
(HCs) were recruited from the local community, interviewed with the M.I.N.I., and none showed any history of 
psychiatric disorders. Ten subjects out of 165 HCs who participated in the MRI experiment were excluded based 
on M.I.N.I. and on the quality check of MRI. The data of age and sex matched 92 HCs with no or low depressive 
symptoms (i.e., BDI <= 10) were used for training classifiers for all MDDs. For development of melancholic 
MDD biomarker, the data of 65 melancholic MDD patients out of 92 MDDs, and age and sex matched 65 HCs 
were included (Table 1 and Supplementary Table S1a). The number of patients and healthy controls were set 
to be equal, in order to develop a classifier unbiased toward either group. Prior to the administration of any 
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experimental procedure, written informed consent was obtained from all participants. For the training dataset of 
the all MDD classifier, we used all the melancholic and non-melancholic MDD data collected from four different 
sites to evaluate the entire heterogeneous depression cohort. For the melancholic MDD classifier, the training 
dataset was limited to have the subtype of melancholia (based on M.I.N.I.) with moderate depression symptoms+ 
for patients based on the Beck Depression Inventory28 (BDI-II score 17 or higher). For scores of the Japanese 
version of national adult reading test (JART)29, which was used to estimate the intelligence quotient (IQ), there 
were eleven missing data in HCs of the training dataset. Additional details on clinical populations can be found 
in the Supplementary Table S1a–c. The experiments were carried out in accordance with relevant guidelines and 
regulations, all our experimental protocols were approved by the Ethics Committee of Hiroshima University, and 
informed consent was obtained from all subjects.
Figure 1. The integrated pipeline for depression biomarker development. Patients were recruited from local 
clinics. Resting-state fMRI and structural T1 data were collected using the identical scanner for each subject. 
Neuroimaging data analysis including preprocessing, functional correlation, and classifier development were 
performed by integrated scripts.
Melancholic 
MDD
Healthy 
Control P-value
No. of participants 65 65 NA
Sex (Male/Female) 38/27 32/33 p = 0.29
Age (Mean (SD)) 43.7 (12.8) 43.6 (10.2) p = 0.92
Self-rating depression scale(BDI-II, Mean (SD)) 31.2 (8.2) 3.6 (3.1) p = 0.000***
Observer-rated depression scale (HAMD-17, Mean (SD)) 19.9 (5.2) N/A NA
IQ (JART, Mean (SD)) 108.3 (10.6) 111.9 (8.6) p = 0.047*
Handedness (left/right) 0/65 0/65 NA
Melancholia (No.%) 100 0 NA
Table 1. Demographic and clinical information of the subject of melancholic MDD classifier. The differences 
between melancholic MDD and healthy controls were evaluated by two-tailed t-test for age, BDI-II, and JART 
respectively, whereas it was evaluated by chi-squared test for sex. ***p < 0.001, *p < 0.05.
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Measures of depression and depressive symptoms. The Beck Depression Inventory (BDI) is one of 
the most frequently used instruments for measuring depression and depressive symptoms as a self-rating scale. 
Additionally, the Hamilton Rating Scale for Depression (HAMD)30 was used to assess the pharmacological treat-
ment effects as an observer rating scale.
experimental protocol and data acquisition. The following common instructions and settings were 
used in all the sites. In the scan room with dimmed lights, participants were required to keep looking at a cross 
mark in the center of the monitor screen, think of nothing in particular, and not to sleep. Details of scan parame-
ters for MRI data acquisition and procedure in each site were shown in Supplementary Table S2.
neuroimaging data preprocessing and interregional correlations. T1-weighted structural image 
and resting state functional images were preprocessed using SPM8 (Wellcome Trust Centre for Neuroimaging, 
University College London, UK) on Matlab R2014a (Mathworks inc., Massachusetts, USA). The functional 
images were preprocessed with slice-timing correction and realignment to the mean image. Then, using the nor-
malization parameters obtained through the segmentation of the structural image aligned with the mean func-
tional image, the fMRI data was normalized and resampled in 2 × 2 × 2 mm3 voxels. Finally, the functional images 
were smoothed with an isotropic 6 mm full-width half-maximum Gaussian kernel. After these preprocessing 
steps, a scrubbing procedure31 was performed to exclude any volume (i.e., functional image) with excessive head 
motions, based on the frame-to-frame relative changes in time series data. In order to keep data quality high 
enough for the subsequent analyses, we only included the subject data with more than 50% of the volumes sur-
vived in the time series (see Supplementary Table S3 for a summary of head motion).
For each individual, the time course of fMRI data was extracted for each of 137 regions of interests (ROIs), 
anatomically defined in the Brainvisa Sulci Atlas (BSA; http://brainvisa)32,33 covering the entire cerebral cor-
tex. We did not incorporate the cerebellum in the construction of a classifier, because for many participants in 
site 1, the cerebellum was truncated in their structural and functional images. After applying a band-pass filter 
(0.008–0.1 Hz), the following nine parameters were linearly regressed out: the six head motion parameters from 
realignment; the temporal fluctuation of the white matter; that of the cerebrospinal fluid; and that of the entire 
brain. A pair-wise Pearson correlations between 137 ROIs were calculated to obtain a matrix of 9,316 FCs for each 
participant. Details of classification algorithm for FC selections were described in the following section.
Classification algorithm for FC selections. By combining the following two machine learning algo-
rithms, we developed a melancholic MDD classifier with identification of characteristic FCs. As the first algo-
rithm, L1-regularized sparse canonical correlation analysis (L1-SCCA)34 was applied to reduce the number of 
features to exclude the effects of nuisance variables (NVs) that may cause catastrophic over-fitting. L1-SCCA 
excluded the effects of nuisance variables (NVs) including sex, age, and scanner type (i.e., four different scanners 
with two different manufacturers; see the subsection of Supplementary Information entitled “Feature selection 
with reduction of nuisance variable effects” for details). As the second algorithm, sparse logistic regression (SLR)35 
was applied to identify small number of features with high contribution to classification. The SLR algorithm 
decides the final number of features based on the principle of Automatic Relevance Determination (ARD)36, 
completely automatically without any meta-parameter. The method uses a sequential process of nested-feature 
selection and leave-one-out cross validation (LOOCV) in order to avoid information leakage and over-optimistic 
results5. Our machine learning algorithm was a combination of nested cross validation and LOOCV. In order to 
have more than twenty subjects per fold, we used 6-fold CV for the melancholic MDD classifier development. At 
the end of LOOCV, the output of the logistic regression classifier was used to compute the classification accuracy. 
The stability and robustness of the selection of the FCs in the LOOCV by evaluating their cumulative absolute 
weights = ∑ =c w ,
k
i
N
i
k
1  where N is the number of LOOCV folds (i.e. the number of subjects), and wki is the weight 
associated with the k-th FC during the i-th LOOCV fold. The greater magnitude of ck indicates a more significant 
contribution by the k-th FC to the classification into melancholic MDD and HC, throughout the LOOCV. The 
more detailed description of this algorithm with some figures are found in the methods section of the autism 
spectrum disorder paper37. The original code developed for the autism spectrum disorder classification is availa-
ble as well (for access, please contact the server administrator of ATR Brain Information Communication 
Research Laboratory: http://asd-classifier@atr.jp).
Generalization to independent cohorts for validation. An independent external validation cohort 
was formed at the National Institute of Radiological Sciences in Chiba, Japan. Based on M.I.N.I., the participants 
(n = 51, Supplementary Table S1b) were evaluated on lifetime history of psychiatric disorders. None of the MDD 
patients (n = 11) had comorbid psychiatric disorders, and none of the healthy controls (n = 40) had any somatic, 
neurological, or psychiatric disorders and no history of current or previous drug abuse. All the participants were 
antidepressant and antipsychotic drug-free for more than 1 month on the day of MRI scan. All participants 
provided written informed consent before the study. The study protocol was approved by the Radiation Drug 
Safety Committee and by the institutional review board of the National Institute of Radiological Sciences, in line 
with the ethical standards established in the 1964 Declaration of Helsinki and its later amendments. Details of 
generalization to other psychiatric disorders and statistical methods on examining the changes of each FC with 
antidepressant treatments are shown in Supplementary Information.
Pharmacological treatment effects. Twenty-five patients with melancholic depression in the training 
dataset had an additional MRI scan after 6 weeks of treatment with antidepressants (SSRI; see Supplementary 
Table S1c). Because this is an observational study and not a clinical trial, it was not possible to have a placebo or 
no treatment control group. Although it was a critical issue, based on our hypothesis, we applied the classifier to 
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this post-treatment dataset to examine if all the identified functional connections would be uniformly resolved 
following treatment, or whilst some functional connections fully resolve, others do not, or are even worsened by 
the pharmacological treatments.
Results
Classification of melancholic MDD and generalization to an independent cohort. Classification 
was first performed by feature-selection from all 9,316 connections using L1-SCCA and SLR, and then the 
weighted linear summation (WLS, linear discriminant function) of the identified functional connections 
was evaluated. First, we tried this algorithm to all MDD (n = 184). However, a leave-one-out cross validation 
(LOOCV) revealed a classification accuracy of only 60% (AUC 0.62, sensitivity 59%, specificity 62%). Next, we 
focused on a more drug-responsive subtype, melancholic MDD. Then, the LOOCV result on the melancholic 
MDD (n = 130, Table 1) revealed a classification accuracy of 84% (AUC 0.91, sensitivity 80%, specificity 88%; 
p = 0.002 with a permutation test). We then tested the classifier on an independent cohort from a different site 
(n = 51), which revealed an accuracy of 69% (AUC 0.69, sensitivity 64%, specificity 70%; p = 0.040 with a per-
mutation test, Supplementary Fig. S1a–d). Together, even with the limitation of small sample size, these results 
provided initial evidence that the classifier was moderately generalizable.
Functional connections underlying classification. We then examined the neural basis of melancholic 
MDD classifier. The sparse classification algorithm identified 10 functional connections (FCs) as listed in Table 2. 
Ten FCs were sorted based on its contribution level. The ROIs included in the identified FCs are shown on a glass 
brain in Fig. 2a. In the distribution of the cumulative absolute weight (Fig. 2b, see Methods), we found that the 
identified 10 FCs were indeed the top 10 most important FCs among the 32 FCs that were selected at least once 
during the LOOCV, indicating the reliability of the FC selection in the present procedure. It was further con-
firmed that the weights of the identified 10 FCs in the LOOCV were significantly nonzero (two-sided Wilcoxon 
signed rank test, p < 0.001) demonstrating their important contribution to the classification of melancholic MDD 
and HC. In order to check for potential scanner or site-related effects, each subject’s weighted linear sum (WLS) 
was colored by site in the histogram of Fig. 2c.
top two functional connections with the highest contributions. We found outstanding contribu-
tions in the top 2 functional connections. Figure 3a shows the plot of each FC’s contribution to the classifier 
(i.e. multiplication of the classifier weight with the difference of each FC between patient and control groups). 
These top two FCs share an adjacent and part-overlapping brain region as one end of connection around the left 
ID Name Lat. BSA atlas (Sulcus) BA r MDD r HC Weight Contribution
1 Inferior Frontal Gyrus opercular part L Diagonal ramus of the lateral fissure 44
−0.018 0.173 −5.17 0.987Dorsomedial Prefrontal Cortex, 
Supplementary Motor Area: SMA, 
Pre-SMA, Frontal Eye Fields
R Median frontal sulcus 6, 8, 9
2 Dorsolateral Prefrontal Cortex, Middle Frontal Gyrus L Intermediate frontal sulcus 46 0.123 −0.065 5.20 0.978
Posterior Cingulate Cortex, Precuneus L Internal parietal sulcus 7, 23, 31
3 Thalamus L Thalamus —
0.050 0.208 −3.27 0.517Anterior Cingulate Cortex, Posterior 
Cingulate Cortex R Subcallosal sulcus
23, 24, 
33
4 Inferior Frontal Gyrus Triangular part L Inferior frontal sulcus 45
0.286 0.407 −3.75 0.454
Inferior Frontal Gyrus opercular part R Inferior precentral sulcus 44, 6
5 Lingual Gyrus L Anterior intralingual sulcus 18
0.166 0.072 4.08 0.384
Middle Occipital Gyrus R Lobe occipital 19
6 Caudate L Caudate —
−0.167 −0.067 −2.97 0.297
Cuneus L Cuneal sulcus 18
7 Lingual Gyrus L Posterior intra-lingual sulcus 18
0.251 0.078 1.52 0.263
ParaHippocampus, Fusiform Gyrus R Collateral fissure 30,37
8 Middle Cingulate Cortex L Calloso-marginal posterior fissure 23
−0.073 −0.168 2.68 0.255
Calcarine L Occipito-polar sulcus 17
9 Inferior Temporal Gyrus L Median occipito-temporal lateral sulcus 20 −0.093 0.015 −1.41 0.152
Post Central Gyrus L Central sulcus 3
10 Inferior Temporal Gyrus L Median occipito-temporal lateral sulcus 20 0.053 0.135 −1.03 0.084
Superior Parietal Gyrus R Superior parietal sulcus 7
Table 2. Identified 10 FCs for the melancholic MDD classifier. The averaged functional correlation value of 
MDDs (rMDD) and HCs (rHC) are shown for each FC. As the patient group was always the positive class in the 
classifier, the sign of weight was positive when rMDD > rHC, and negative when rMDD < rHC. Contribution 
was calculated as (rMDD - rHC) × weight.
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DLPFC/IFG as shown in Fig. 3b. For the sign of these FCs, FC#1 showed less or no positive functional corre-
lations in MDDs, compared to HCs who showed positive correlations between the ROIs of left inferior frontal 
gyrus (IFG opercular, BA44) in executive control network and right DMPFC (BA9)/frontal eye field (FEF, BA8)/
supplementary motor area (SMA, BA6) in salience network. On the other hand, FC#2 shows positive functional 
correlations in melancholic MDDs, compared to HCs who have no or negative correlations between the ROIs of 
left dorsolateral prefrontal cortex (DLPFC, BA46) in executive control network and left posterior cingulate cortex 
(PCC)/Precuneus in default mode network.
Effect of treatment with antidepressants. A subset of our melancholic MDD cohort (n = 25), who were 
treated with antidepressants as part of their routine clinical care (i.e., escitalopram in the majority of cases), had 
a further post-treatment rsfMRI scan at 6–8 weeks to evaluate the effect on functional connectivity. First, across 
these subjects, both the Beck Depression Inventory-II (BDI) score and the Hamilton Rating Scale for Depression 
(HAMD) were significantly reduced (Mean(SD): BDI Pre = 31.3 (7.48), BDI Post = 18.7 (12.2), paired t-test 
results on BDI: p = 7.26 × 10-7; and HAMD Pre = 19.1 (5.63), HAMD Post = 11.3 (5.41), paired t-test results on 
HAMD: p = 7.29 × 10-7).
Next, we evaluated the specific effect of antidepressant treatment on each FC of the melancholic MDD classi-
fier. Based on the hypothesis that antidepressants would normalize the post-treatment MDDs’ FC values closer to 
those of HCs’, the difference in average FC values between post and pre antidepressant treatment was statistically 
compared to the difference between healthy control and MDD for each FC (Fig. 3c). FC values were multiplied 
by the sign of each weight to keep consistent directions; positive for MDD, negative for HC, and p-values were 
corrected using FDR. For each connection, p-value using Welch’s t test with FDR correction was as follows. FC#1: 
p = 0.328, FC#2: p = 0.012, FC#3: p = 0.083, FC#4: p = 0.328, FC#5: p = 0.328, FC#6: p = 0.328, FC#7: p = 0.328, 
FC#8: p = 0.328, FC#9: p = 0.328, FC#10: p = 0.328. The over-representation of the same values is because of the 
Benjamini-Hochberg FDR correction, and uncorrected p-value for each FC was as follows. FC#1: p = 0.318, FC#2: 
p = 0.001, FC#3: p = 0.016, FC#4: p = 0.166, FC#5: p = 0.312, FC#6: p = 0.244, FC#7: p = 0.162, FC#8: p = 0.291, 
FC#9: p = 0.181 FC#10: p = 0.327. We found that all but two of the FCs were shifted in a normalized direction (i.e. 
in the direction of healthy controls) after the treatment, and the result of uncorrected p-value showed difference 
of treatment effects on two of the FCs. This could be because of heterogeneous influence of pharmacological 
treatment instead of regression toward the mean as a temporal change. However, one FC changed significantly 
in the opposite direction - away from that of healthy controls. Interestingly, this was the FC of left DLPFC and 
left PCC/Precuneus FC, which had the second highest contribution to the classifier (FC#2, pairwise comparison 
between the classifier contribution and the change by antidepressant treatments (p = 0.012)). Note that in all 
panels of Fig. 3c–e, a positive change is in the direction of MDD, and a negative change is towards healthy control: 
Figure 2. The identified 10 functional connections for the melancholic MDD biomarker. (a) Brain regions 
included in the identified functional connections (FCs) of the melancholic MDD classifier. Cumulative absolute 
weight of 32 FCs in total, which were selected at least once throughout the LOOCV. The identified 10 FCs are 
shown in red, and the rest of 22 FCs are in Gray. (c) Distribution of each subject’s weighted linear sum (WLS) 
was colored by site, in order to check for any potential scanner or site related effect (melancholic MDD: n = 65, 
HC: n = 65).
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this is because we multiply FC or differences of FC with the sign of the classifier weight in the melancholic MDD 
classifier.
Moreover, results of FC#1 (i.e., SN and ECN connectivity: SN-ECN) and FC#2 (i.e., DMN and ECN connectiv-
ity: DMN-ECN) changes with the antidepressant treatment were examined more in detail. In order to show early 
response and treatment outcome, all four conditions were plotted in Fig. 3d (healthy control (HC): n = 65, 0–2 
weeks and 6–8 weeks treatment MDD (Dep0–2w, Dep6–8w for each period): n = 25, and an independent cohort of 
euthymic MDDs, who were fully remitted following long-term treatment with antidepressants (Euthymic: n = 34, 
Supplementary Table S1c). One way ANOVA yielded different significant variation among conditions for each 
FC (FC#1: F(3,145) = 7.37, p = 0.000, FC#2: F(3,145) = 10.9, p = 0.000). For FC#1, antidepressant treatments rea-
sonably normalized the FC1 towards HC. Tukey’s HSD showed significant differences between HC and Dep0–2w 
(p = 0.008), and Dep0–2w and Euthymic (p = 0.001). The other contrasts were not significant: HC and Dep6–8w 
(p = 0.137, n.s.), HC and Euthymic (p = 0.999, n.s.), 0–2w and 6–8w (p = 0.331, n.s.), and Dep6–8w and Euthymic 
(p = 0.173, n.s.). On the other hand, for FC#2, there was no normalization effect observed in Dep6–8w. The same 
post-hoc test (Tukey’s HSD) kept showing significant differences not only between HC and Dep0–2w (p = 0.008), 
but also between HC and Dep6–8w (p = 0.000). In addition, there were significant differences between euthymic 
group and Dep0–2w (p = 0.008), and Dep6–8w (p = 0.000) in the same way. The rest of conditions showed no signif-
icance: HC and Euthymic (p = 0.971, n.s.), 0–2w and 6–8w (p = 0.606, n.s.).
One might assume that there might be some compensatory relationship between FC#1 and FC#2. That is, 
more positive value in FC#2 might possibly help to have more negative value in FC#1. The answer was shown in 
Fig. 3e. No compensatory relationship was observed between FC#1 and FC#2 changes (r = -0.147, p = 0.483, n.s.) 
Assuming that both FC#1 and FC#2 are equally contributing to prediction of remission, the blue to red gradient 
Figure 3. Individual functional connection changes from before to after antidepressant treatments. (a) 
Contribution of each of 10 FCs to the melancholic depression classifier. (b) Top two FCs with dominant 
contributions. There was a partially-overlapped region of both FCs in the left DLPFC. (The rendering tool: 
MRIcroGL 64-bit 12 June 2015, https://www.nitrc.org/projects/mricrogl) (c) For each FC, the post minus 
pre antidepressant treatment difference in average FC values of melancholic MDD (Post and Pre, n = 25) was 
compared with that difference between healthy control (HC, n = 65) and melancholic MDD (MDD, n = 65), 
and only the FC#2 showed significant difference (p < 0.05). The box plot represents the 95% confidence interval 
around the mean. (d) FC#1 and FC#2 changes with the antidepressant treatment were examined. The bar graphs 
represent mean values with standard error (SE) bars. Compared to healthy control (HC, n = 65), pre-treatment 
(Dep0–2w, n = 25), post-treatment (Dep6–8w, n = 25), and an independent cohort of remitted depression 
patients (Euthymic, n = 34). (e) Changes in FC#1 and FC#2 for the 25 melancholic MDD patients with 
antidepressant treatments (blue dots: remit, n = 6, and pink dots: non-remit, n = 19). The blue to red gradient 
represents the probabilistic decision boundary of the logistic regression, where stronger blue (remit) and red 
(non-remit) colors are associated with a large probability of being in class and weaker colors represent increased 
uncertainty. *p < 0.05, **p < 0.01.
8Scientific RepoRtS | (2020) 10:3542 | https://doi.org/10.1038/s41598-020-60527-z
www.nature.com/scientificreportswww.nature.com/scientificreports/
represents the probabilistic decision boundary of the logistic regression, where strong red and blue colors are 
associated with a large probability of being in the class of ‘non-remitted’ and that of ’remitted’ respectively. Weaker 
colors represent increased uncertainty. Blue and pink dots show actually remitted (n = 6), and non-remitted 
(n = 19) melancholic MDD patients, and remission was assessed by HAMD score38.
Application to non-melancholic MDD patients. In order to examine a degree of diagnostic specificity 
of the melancholic MDD classifier, we also tested the classifier on 27 non-melancholic MDD and 27 additional 
control subjects. When it was applied to the non-melancholic MDD group, generalization accuracy was 69% 
(sensitivity 68%, specificity 71%, and AUC 0.72), suggesting that the classifier might be to some extent specific 
to melancholic MDD. As shown in the density distributions of the weighted linear sum (WLS), the distribu-
tion of melancholic MDD and healthy control were significantly different (Fig. 4a p = 6.3 × 10–14, Benjamini–
Hochberg-corrected Kolmogorov–Smirnov test), and non-melancholic MDD appeared to be shifted toward the 
direction of the healthy control group along the axis of the melancholic MDD classifier, but this did not reach 
significance level (Fig. 4b, p = 0.14, Benjamini–Hochberg-corrected Kolmogorov–Smirnov test).
Application to treatment-resistant MDD. In addition to the non-melancholic MDD patients, we applied 
the classifier to an independent cohort of treatment-resistant MDD (16 patients, 16 controls). The accuracy was 
72% (sensitivity 69%, specificity 75%, and AUC 0.68) and there was no significant difference between the patient 
and control distributions (Fig. 4c, p = 0.81, n.s., Benjamini–Hochberg-corrected Kolmogorov–Smirnov test).
Application to other psychiatric disorders. To further evaluate the specificity of the classifier, we uti-
lized two other psychiatric cohorts: autism spectrum disorder (ASD; 74 patients, 36 controls) and Schizophrenia 
spectrum disorder (68 patients, 102 controls). For the ASD cohort, accuracy was 55% (sensitivity 53%, specificity 
61%, and AUC 0.63), and as illustrated in the density distributions, there was no difference between patients 
and controls (Fig. 4d, p = 0.97, n.s., Benjamini–Hochberg-corrected Kolmogorov–Smirnov test). In the schiz-
ophrenia spectrum disorder cohort, accuracy was 41% (sensitivity 40%, specificity 41%, and AUC 0.44). In 
fact, the schizophrenia spectrum disorder patients’ distribution was located significantly on the opposite side 
to MDD with respect to healthy control (Fig. 4e, p = 0.08, n.s., Benjamini–Hochberg-corrected Kolmogorov–
Smirnov test). Overall, these results support a degree of diagnostic specificity of the melancholic MDD classifier. 
Generalization of the ASD classifier and the Schizophrenia classifier to our MDD cohort was examined and 
reported elsewhere37,39.
Discussion
The purpose of this study was to develop a melancholic MDD biomarker, and to explore its sensitivity to treat-
ment. In particular, we aimed to test whether functional connectivity changes were influenced homogenously, 
or heterogeneously, as a window into understanding why treatments might have a limited effect, and potentially 
even identifying candidate targets for future treatment. Ten FCs were selected by our sparse machine learning 
algorithm as the melancholic depression biomarker. The validity of the melancholic MDD biomarker was demon-
strated by generalization to a completely independent validation cohort, and its specificity was demonstrated 
by the following applications of the classifier to other subtypes and psychiatric disorders. Moreover, this study 
showed that antidepressants had a heterogeneous effect on the functional connectivity underlying depression, 
and this biomarker allowed us to identify and localize the effect of antidepressant action on different functional 
connections. Specifically, it was highlighted that the FC with the second highest contribution did not show signif-
icant normalization after 6–8 weeks of antidepressant treatments, whereas the rest of the FCs were normalized.
Out of ten FCs, the top two FCs with outstanding contributions in the melancholic depression classifier 
included the FCs with left IFG in ECN and right DMPFC/FEF/SMA in SN for FC#1, and left DLPFC/IFG in 
ECN and PCC/Precuneus in DMN for FC#2. Although it is still difficult to define their precise neuropsycho-
logical roles in depression, previous studies provide some clues. These regions have been associated with cogni-
tive flexibility, for instance, assessed with reversal learning tasks40,41, in which depression patients typically have 
functional deficits in. Regarding FC#1 (SN-ECN), previous study showed that increased neural activity in IFG 
and DMPFC were associated with empathic accuracy with compassion meditation training42, and reduced con-
nectivity between DMPFC-IFG was observed in depressed adolescents during cognitive reappraisal of emotional 
images43. In addition, priming-TMS studies shows that the DMPFC has a causal role in forming social-relevant 
impression including face-adjective pair, and processing verbal emotional stimuli44,45. As for FC#2 (DMN-ECN), 
bilateral DLPFC/IFG have been associated with attention control and conflict processing46, and PCC/Precuneus 
have been associated with anhedonic depression and anxious arousal47.
From a general perspective, the correlation between a drug and a functional connection could arise for any 
one of three reasons: as a cause, epiphenomenon, or compensation for other changes observed in the disorder. 
In the case of the left DLPFC/IFG - PCC/Precuneus, the second and third possibilities seem unlikely for the fol-
lowing reasons. The epiphenomena hypothesis assumes that the increase or decrease of FC#2 (DMN-ECN) could 
occur simultaneously with depressive symptoms but not directly in causal relationships. As a remedy for depres-
sion, antidepressant therapy reduces severity of depression (i.e., BDI, HAMD scores). Although this hypothesis 
predicts decrease in FC#2 (DMN-ECN), this is against our experimental observation (Fig. 3d). The compensation 
hypothesis assumes that the FC#2 (DMN-ECN) increase actively compensates deteriorating effects induced by 
the abnormal changes in other FCs in depression, including FC#1 (SN-ECN) increase. This hypothesis predicts 
positive correlations between changes in FC#1 (SN-ECN) and FC#2 (DMN-ECN), but we did not observe the 
predicted positive correlations after antidepressants therapy (Fig. 3e).
On one of the recently suggested reasons on why antidepressants including SSRI might not seem to affect the 
FC#2 (DMN-ECN) immediately, there was a review paper pointing a problem of antidepressant treatment using 
9Scientific RepoRtS | (2020) 10:3542 | https://doi.org/10.1038/s41598-020-60527-z
www.nature.com/scientificreportswww.nature.com/scientificreports/
SSRI48. The authors suggested that the depression symptom reduction is not achieved by the direct pharmacolog-
ical properties of SSRI, but by the brain’s compensatory responses to restore homeostasis. That may explain why 
it takes several weeks to achieve the SSRI treatment response outcome rather than 30 minutes after taking the 
medicine like aspirin. This hypothesis cannot be directly applied to our fMRI results, because the previous PET 
study showed human serotonin transporter exists more in midbrain49 rather than in cerebral cortex. However, it 
could be indirectly associated with our results, showing that the FC#2 (DMN-ECN) moved to the opposite direc-
tion of normalization once, and then gradually coming back to the normalizing direction after entering into the 
Figure 4. Generalization performance of the melancholic MDD biomarker to other subtypes and psychiatric 
disorders. To assess the difference in density distributions of WLS, Benjamini–Hochberg-corrected 
Kolmogorov–Smirnov test was applied to the comparison between each disorder and its healthy control. (a) 
Melancholic MDD (Mel. MDD) and healthy control (HC) were significantly different in density distribution 
of WLS (p = 6.3 ×   10–14). For other subtypes of MDD and psychiatric disorders, there was no significant 
difference was observed when the melancholic MDD classifier was applied; (b) non-melancholic MDD (Non 
Mel. MDD) and HC (p = 0.14), (c) treatment-resistant MDD (Treat. Res. MDD) and HC (p = 0.81), (d) autism 
and HC (p = 0.97), and (e) schizophrenia and HC (p = 0.08). ***p < 0.001.
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euthymic state. It is impossible to deny the possibility of placebo effect in this paper, because we do did not have 
any appropriate control group as this was an observational study, not a clinical trial. The potential confounding 
component here is the time course effect which would make the FCs to regress toward the mean. Although this is 
the largest limitation, for example, if our results could just be a placebo effect or due to uniform temporal changes 
of functional correlations, then, all the functional connections should most probably regress toward the same 
direction to normalization, as BDI and HAMD depression symptom scores were significantly improved on aver-
age. However, our data showed different functional connection changes among the identified 10 FCs as shown 
in Fig. 3c (eight FCs to normalization, one FC with no change, and one FC to the opposite direction). Therefore, 
though it is the largest limitation that there is no placebo group in this study, there would be a high possibility that 
our data were able to examine the functional connection specific pharmacological effects.
In addition to a wealth of correlative evidence that links left dorsolateral prefrontal cortex connections to 
depression24,50–57, there is other evidence that suggests an active functional relationship. First, it is an established 
target for repetitive transcranial magnetic stimulation (rTMS)58–60 therapy for depression. Second, recent neu-
rofeedback treatment directly targeting FC#2 (DMN-ECN) connectivity has been found to be effective61–63. 
Therefore although more studies are needed, the current evidence points toward a causal influence of DLPFC 
connectivity and depression.
Limitations
There were several limitations in this study. Given the highly heterogeneous nature, it is important to note limita-
tions of the interpreting rsfMRI results in depression. First, as a limitation of resting state data, we cannot control 
some spontaneous thoughts or mental activity, and this also could affect stability of the data. Second, although 
we specifically focused on melancholic depression and identified 10 FCs, this may still limit high classification 
accuracy64 as some previous papers suggest the effectiveness of an additive model of categorical diagnosis and 
symptom dimensions65. In addition, we had a small sample size of independent drug-free cohort (with neither 
antidepressant nor antipsychotic use for more than one month). The most critical limitation in this study was that 
antidepressant effects were tested on relatively small size of MDD cohort with pre- and post- treatments, and we 
did not have a placebo or no-treatment group because of ethical issues and difficulty in recruitment. This needs 
to be tested on a larger cohort in the future. However, the top two critical FCs with especially high contributions 
included the brain regions which have been persistently implicated across previous depression studies. Ideally, 
future studies need to track the longer-term profile of FC#2 (DMN-ECN) in larger data sets. Although FC#2 
(DMN-ECN) was still abnormal at 6–8 weeks after antidepressant treatments, it was normalized in the euthymic 
group, which might include only the patients who are responsive to treatments though.
conclusions
This study provides novel evidence on the importance of the critical functional connection between PCC/
Precuneus and left DLPFC/IFG (DMN-ECN), which did not show any improvement right after the antidepres-
sant treatments. Our data not only validated the development of rsfMRI-based melancholic depression biomarker 
in understanding mechanisms of disorder and treatment, but also suggested the possibility that combined therapy 
of antidepressants and targeted neurostimulation/neurofeedback could be an optimal strategy to pursue in the 
future therapeutic studies.
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